US › Healthcare

Inovio Pharmaceuticals Inc (INO)

US · Healthcare · Biotechnology

$1.22-15.86%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.0M

EPS

$-0.07

EPS estimate

$-0.25

EPS came in at -0.07 against a street estimate of -0.25 — a beat of 72.0%.

Key statistics

Market cap

$149.9M

Forward P/E

16.6

P/B

39.27

Book value

$0.05

EPS (TTM)

$-0.90

52-week high

$2.72

52-week low

$0.56

50-day MA

$1.17

200-day MA

$1.27

Beta

1.73

Analyst view

Analysts rate Inovio Pharmaceuticals Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $5.33.

Shareholding

Insiders

0.33%

Institutions

46.78%

Largest institutional holders

Fund	Stake
FMR Inc	8.18%
Jupiter Topco LLC	5.00%
Vanguard Capital Management, LLC	3.53%
Boxer Capital Management, LLC	2.75%
ADAR1 Capital Management LLC	2.07%
D. E. Shaw & Co LP	1.31%
Two Sigma Investments LLC	1.20%
Eversept Partners, LP	1.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Inovio Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.